Premium
Treatment of acute myelogenous leukemia in adults with N 4 ‐behenoyl‐1‐β‐D‐arabinofuranosylcytosine
Author(s) -
Kimura Kiyoji,
Ohno Ryuzo,
Amaki Ichita,
Hattori Kenichi,
Hirota Yutaka,
Hoshino Akira,
Ichimaru Michito,
Ito Munemoto,
Kimura Ikuo,
Maekawa Tadashi,
Masaoka Toru,
Nakamura Toru,
Ogawa Makoto,
Oguro Masao,
Ohta Kazuo,
Osamura Shigeyuki,
Shimoyama Masanori,
Takaku Fumimaro,
Uzuka Yoshiro,
Yamada Kazumasa
Publication year - 1985
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19851015)56:8<1913::aid-cncr2820560803>3.0.co;2-w
Subject(s) - medicine , nausea , anorexia , vomiting , gastroenterology , complete remission , leukemia , acute leukemia , cytarabine , chemotherapy
Forty‐five previously‐untreated adult patients with acute myelogenous leukemia (AML) were treated with N 4 ‐behenoyl‐1‐β‐D‐arabinofuranosyl‐cytosine (BHAC) in a multi‐institutional cooperative study. Among 41 evaluable patients, 15 (36.6%) achieved complete remission (CR) and 10 (24.4%) achieved partial remission by daily administration of 3 to 8 mg/kg of BHAC. Higher daily doses (5 mg/kg or more) produced higher CR rates, and all of the CR were observed among the patients receiving a total BHAC dosage of 50 mg/kg or more in a period of 10 days or more. The side effects were mild and acceptable: nausea–anorexia was observed in 27% of the patients and vomiting in 17%. The results of this study thus indicate BHAC to be effective for remission induction of AML, and to deserve further clinical trials in combination with other anti‐leukemic drugs. Cancer 56: 1913‐1917, 1985.